基于抗原85B与ESAT-6融合蛋白的结核亚单位疫苗在豚鼠气溶胶模型中的保护作用
Protective effect of a tuberculosis subunit vaccine based on a fusion of antigen 85B and ESAT-6 in the aerosol guinea pig model.
作者信息
Olsen Anja W, Williams Ann, Okkels Limei M, Hatch Graham, Andersen Peter
机构信息
Department of Infectious Disease Immunology, Statens Serum Institute, Copenhagen, Denmark.
出版信息
Infect Immun. 2004 Oct;72(10):6148-50. doi: 10.1128/IAI.72.10.6148-6150.2004.
Abstract
A fusion protein of antigen 85B (Ag85B) and ESAT-6 administered in cationic lipid vesicles conferred a highly significant level of protection against Mycobacterium tuberculosis in the guinea pig aerosol model of infection. The protection was manifested as delayed clinical illness and prolonged survival. Neither Ag85B nor ESAT-6 (independently or as a cocktail) induced significant protection in this model.
摘要
在阳离子脂质囊泡中给药的抗原85B（Ag85B）和早期分泌性抗原靶6（ESAT-6）融合蛋白，在豚鼠气溶胶感染模型中对结核分枝杆菌具有高度显著的保护作用。这种保护表现为临床疾病延迟和生存期延长。在该模型中，单独的Ag85B或ESAT-6（或二者混合）均未诱导出显著的保护作用。
相似文献
1
Protective effect of a tuberculosis subunit vaccine based on a fusion of antigen 85B and ESAT-6 in the aerosol guinea pig model.
Infect Immun. 2004 Oct;72(10):6148-50. doi: 10.1128/IAI.72.10.6148-6150.2004.
2
Alteration of epitope recognition pattern in Ag85B and ESAT-6 has a profound influence on vaccine-induced protection against Mycobacterium tuberculosis.
Eur J Immunol. 2006 Dec;36(12):3346-55. doi: 10.1002/eji.200636128.
3
Protection of macaques against Mycobacterium tuberculosis infection by a subunit vaccine based on a fusion protein of antigen 85B and ESAT-6.
Vaccine. 2005 Apr 15;23(21):2740-50. doi: 10.1016/j.vaccine.2004.11.051.
4
Efficacy of recombinant bacille Calmette-Guérin vaccine secreting interleukin-15/antigen 85B fusion protein in providing protection against Mycobacterium tuberculosis.
J Infect Dis. 2008 May 1;197(9):1263-74. doi: 10.1086/586902.
5
Recombinant BCG coexpressing Ag85B, ESAT-6 and mouse-IFN-gamma confers effective protection against Mycobacterium tuberculosis in C57BL/6 mice.
FEMS Immunol Med Microbiol. 2007 Dec;51(3):480-7. doi: 10.1111/j.1574-695X.2007.00322.x. Epub 2007 Oct 4.
6
Immunogenicity and protective efficacy of a fusion protein vaccine consisting of antigen Ag85B and HspX against Mycobacterium tuberculosis infection in mice.
Scand J Immunol. 2011 Jun;73(6):568-76. doi: 10.1111/j.1365-3083.2011.02531.x.
7
Chimaeric protein improved immunogenicity compared with fusion protein of Ag85B and ESAT-6 antigens of Mycobacterium tuberculosis.
Scand J Immunol. 2006 Nov;64(5):476-81. doi: 10.1111/j.1365-3083.2006.01812.x.
8
The Ag85B protein of Mycobacterium tuberculosis may turn a protective immune response induced by Ag85B-DNA vaccine into a potent but non-protective Th1 immune response in mice.
Cell Microbiol. 2007 Jun;9(6):1455-65. doi: 10.1111/j.1462-5822.2007.00884.x. Epub 2007 Jan 22.
9
The development and preliminary evaluation of a new Mycobacterium tuberculosis vaccine comprising Ag85b, HspX and CFP-10:ESAT-6 fusion protein with CpG DNA and aluminum hydroxide adjuvants.
FEMS Immunol Med Microbiol. 2010 Jun 1;59(1):42-52. doi: 10.1111/j.1574-695X.2010.00660.x. Epub 2010 Feb 17.
10
Protection against tuberculosis induced by oral prime with Mycobacterium bovis BCG and intranasal subunit boost based on the vaccine candidate Ag85B-ESAT-6 does not correlate with circulating IFN-gamma producing T-cells.
Vaccine. 2009 Jan 1;27(1):28-37. doi: 10.1016/j.vaccine.2008.10.034. Epub 2008 Oct 31.
引用本文的文献
1
An intranasal nanoparticle vaccine elicits protective immunity against Mycobacterium tuberculosis.
Vaccine. 2024 Sep 17;42(22):125909. doi: 10.1016/j.vaccine.2024.04.055. Epub 2024 May 3.
2
Secretory System Components as Potential Prophylactic Targets for Bacterial Pathogens.
Biomolecules. 2021 Jun 15;11(6):892. doi: 10.3390/biom11060892.
3
Fusion of Dendritic Cells Activating Rv2299c Protein Enhances the Protective Immunity of Ag85B-ESAT6 Vaccine Candidate against Tuberculosis.
Pathogens. 2020 Oct 22;9(11):865. doi: 10.3390/pathogens9110865.
4
Ensilication Improves the Thermal Stability of the Tuberculosis Antigen Ag85b and an Sbi-Ag85b Vaccine Conjugate.
Sci Rep. 2019 Aug 8;9(1):11409. doi: 10.1038/s41598-019-47657-9.
5
Heterologous Immunity between Adenoviruses and Hepatitis C Virus (HCV): Recombinant Adenovirus Vaccine Vectors Containing Antigens from Unrelated Pathogens Induce Cross-Reactive Immunity Against HCV Antigens.
Cells. 2019 May 26;8(5):507. doi: 10.3390/cells8050507.
6
Utilization of Staphylococcal Immune Evasion Protein Sbi as a Novel Vaccine Adjuvant.
Front Immunol. 2019 Jan 11;9:3139. doi: 10.3389/fimmu.2018.03139. eCollection 2018.
7
Integrating Non-human Primate, Human, and Mathematical Studies to Determine the Influence of BCG Timing on H56 Vaccine Outcomes.
Front Microbiol. 2018 Aug 17;9:1734. doi: 10.3389/fmicb.2018.01734. eCollection 2018.
8
STING-Activating Adjuvants Elicit a Th17 Immune Response and Protect against Mycobacterium tuberculosis Infection.
Cell Rep. 2018 May 1;23(5):1435-1447. doi: 10.1016/j.celrep.2018.04.003.
9
Use of Soluble Extracellular Regions of MmpL (SERoM) as Vaccines for Tuberculosis.
Sci Rep. 2018 Apr 4;8(1):5604. doi: 10.1038/s41598-018-23893-3.
10
The current status, challenges, and future developments of new tuberculosis vaccines.
Hum Vaccin Immunother. 2018 Jul 3;14(7):1697-1716. doi: 10.1080/21645515.2018.1458806. Epub 2018 May 14.
本文引用的文献
1
Combination of the cationic surfactant dimethyl dioctadecyl ammonium bromide and synthetic mycobacterial cord factor as an efficient adjuvant for tuberculosis subunit vaccines.
Infect Immun. 2004 Mar;72(3):1608-17. doi: 10.1128/IAI.72.3.1608-1617.2004.
2
Specific delayed-type hypersensitivity responses to ESAT-6 identify tuberculosis-infected cattle.
J Clin Microbiol. 2003 May;41(5):1856-60. doi: 10.1128/JCM.41.5.1856-1860.2003.
3
Failure of the Mycobacterium bovis BCG vaccine: some species of environmental mycobacteria block multiplication of BCG and induction of protective immunity to tuberculosis.
Infect Immun. 2002 Feb;70(2):672-8. doi: 10.1128/IAI.70.2.672-678.2002.
4
Protection of mice with a tuberculosis subunit vaccine based on a fusion protein of antigen 85b and esat-6.
Infect Immun. 2001 May;69(5):2773-8. doi: 10.1128/IAI.69.5.2773-2778.2001.
5
Boosting vaccine for tuberculosis.
Infect Immun. 2001 Apr;69(4):2714-7. doi: 10.1128/IAI.69.4.2714-2717.2001.
6
Tuberculosis vaccine development: recent progress.
Trends Microbiol. 2001 Mar;9(3):115-8. doi: 10.1016/s0966-842x(00)01949-1.
7
ESAT-6 subunit vaccination against Mycobacterium tuberculosis.
Infect Immun. 2000 Feb;68(2):791-5. doi: 10.1128/IAI.68.2.791-795.2000.
8
Evaluation of new vaccines in the mouse and guinea pig model of tuberculosis.
Infect Immun. 1998 Jun;66(6):2951-9. doi: 10.1128/IAI.66.6.2951-2959.1998.
9
Effective vaccination of mice against Mycobacterium tuberculosis infection with a soluble mixture of secreted mycobacterial proteins.
Infect Immun. 1994 Jun;62(6):2536-44. doi: 10.1128/iai.62.6.2536-2544.1994.
10
Human T-cell responses to secreted antigen fractions of Mycobacterium tuberculosis.
Infect Immun. 1995 Apr;63(4):1491-7. doi: 10.1128/iai.63.4.1491-1497.1995.
Zotero 插件